Supernus Pharmaceuticals SUPN Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $186.32M+60.8% | $129.9M+87.4% | $152.82M+382% | $144.71M+178% | $115.85M+82.7% | ||
| $182.18M+25.1% | $187.8M+32.2% | $171.25M+17.8% | $140.83M-7.6% | $145.64M-1.4% | ||
| $23.71M-52.0% | $30.1M— | $27.7M-56.7% | $44.02M-35.4% | $49.42M-34.2% | ||
| $731.58M+6.4% | $644.18M-6.1% | $593.89M-7.2% | $738.87M+25.0% | $687.58M+26.3% | ||
| $10.04M-11.4% | $10.53M-8.8% | $10.63M-10.5% | $11.07M-9.8% | $11.34M-12.6% | ||
| $120.67M+3.1% | $124.88M+6.7% | $119.08M+1.8% | $117.02M0.0% | $117.02M0.0% | ||
| $549.71M+9.5% | $569.46M+9.1% | $623.48M+15.4% | $481.31M-14.0% | $502.13M-13.4% | ||
| $1.5B+11.4% | $1.45B+6.2% | $1.42B+5.7% | $1.38B+5.1% | $1.35B+3.3% | ||
| $373.93M+32.7% | $338.17M+15.7% | $330.63M+13.4% | $286.36M-7.2% | $281.77M-10.4% | ||
| $206K-99.9% | $31.26M-90.6% | $370.09M+10.3% | $318.51M-11.1% | $316.59M-15.6% | ||
| 130M0.0% | 130M+232,043% | 130M0.0% | 130M0.0% | 130M0.0% | ||
| $515.58M-5.3% | $517.88M-6.9% | $521.98M-3.5% | $567.1M+12.8% | $544.6M+12.8% | ||
| $1.08B+4.5% | $1.06B+2.5% | $1.05B+4.2% | $1.06B+11.1% | $1.03B+10.9% | ||
| $1.5B+11.4% | $1.45B+6.2% | $1.42B+5.7% | $1.38B+5.1% | $1.35B+3.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Supernus Pharmaceuticals's total assets?
- Supernus Pharmaceuticals (SUPN) holds $1.5B in total assets, up 11.4% year over year.
- How much debt does Supernus Pharmaceuticals have?
- Supernus Pharmaceuticals carries $40.9M in total debt against $1.1B of shareholders' equity, a debt-to-equity ratio of 0.04.
- How much cash does Supernus Pharmaceuticals have?
- Supernus Pharmaceuticals holds $186.3M in cash and equivalents.
- Can Supernus Pharmaceuticals cover its short-term obligations?
- Its current ratio is 1.96 — current assets exceed current liabilities.
- Where does Supernus Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
